Regeneron (REGN) Tops Q4 EPS by $1.06, Revenues Beat; Offers FY19 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Regeneron Pharma (REGN) PT Raised to $480 at Oppenheimer
February 7, 2019 8:15 AM ESTOppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $480.00 (from $440.00) while maintaining a Outperform rating.
Singh commented, "REGN reported 4Q18 sales/earnings and provided a business update on 02/06. The company's Eylea US (and ex-US) sales were 5-9% above OPCO... More
Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
February 6, 2019 3:25 PM ESTBMO Capital analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $410.00 (from $388.00) while maintaining a Market Perform rating, saying they are incrementally positive on earnings.
Skorney commented, "Regeneron reported strong fourth quarter earnings coming in ahead of both top- and... More
UPDATE: Sanofi (SNY), Regeneron (REGN) Report CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
February 4, 2019 5:56 AM EST(Updated - February 4, 2019 5:57 AM EST)
Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) announce the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab), recommending a new indication as an adjunct to correction of other risk factors. Praluent should be used in addition to a maximally tolerated dose of statin or can be used alone in patients intolerant to or inappropriate for statin therapy.
ASCVD is an umbrella term,... More
